Abstract
BackgroundThis study investigated the extent and nature of cardiac morbidity and cause of mortality in patients with Mitroflow structural valve deterioration (SVD).MethodsA retrospective study was performed examining the medical records of patients who had received Mitroflow bioprosthesis between February 2001 and April 2014 and died during this period. A total of 211 patients were identified and included in the analyses. To determine the cause of mortality, cases were divided into three predefined groups: cardiovascular death due to SVD (group 1), cardiovascular death with no SVD (group 2) and non-cardiovascular death without SVD (group 3).ResultsOverall mortality in this study was 7.6% at 1 year, 46.4% at 5 years and 97.2% at 10 years. In group 1, 53 patients (25%) died; in group 2, 59 patients (28%) died; and in group 3, 99 patients (47%) died. Hospitalisation for congestive heart failure was observed in 49.1% in the SVD group vs. 10.2 and 13.1% in the two other groups, p < 0.001. Hospitalisation for endocarditis was also significantly higher in the SVD group (11.3%) than in the two other groups (6.8 and 0%), p < 0.05. Hospitalisation due to myocardial infarction, cerebral stroke, arrhythmia or other cardiac-related diseases was not significantly different between groups.ConclusionStructural valve deterioration in Mitroflow bioprosthesis was associated with a high prevalence of hospital admissions due to congestive heart failure and endocarditis. Patients with Mitroflow bioprosthesis should be systematically and routinely followed with echocardiography, and reoperation should be considered if SVD has developed.
Highlights
Aortic valve replacement has improved life expectancy in patients with severe aortic valve stenosis
A total of 440 patients who received aortic valve replacement with the Mitroflow bioprosthesis were identified from the Western Denmark Heart Registry [9]
In the present study, we describe for the first time cardiac morbidity and cause of death in a patient population that had received a Mitroflow bioprosthesis implantation
Summary
Aortic valve replacement has improved life expectancy in patients with severe aortic valve stenosis. Recent studies have reported early structural valve deterioration (SVD) in the Mitroflow valve compared with the Carpentier-Edwards (CE) Perimount valve [6]. Some studies show a pattern of SVD already 4 years after Mitroflow implantation [7, 8]. This is supported by a recent registry-based study which observed increased reoperation rates for Mitroflow prostheses size 19 and 21 compared with Carpentier-Edwards (CE) Perimount 19 and 21 mm valves [6]. This study investigated the extent and nature of cardiac morbidity and cause of mortality in patients with Mitroflow structural valve deterioration (SVD)
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call